Đang tải…
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis
OBJECTIVE: To compare the safety and efficacy of switching from reference adalimumab to adalimumab biosimilar CT-P17 with continuing reference adalimumab/CT-P17 in active RA. METHODS: This double-blind, phase III study randomized (1:1) subjects with active RA to receive 40 mg (100 mg/ml) CT-P17 or E...
Những tác giả chính: | , , , , , , , , , , , , , , , , , , |
---|---|
Định dạng: | Online Bài viết Texto |
Ngôn ngữ: | English |
Được phát hành: |
Oxford University Press
2021
|
Những chủ đề: | |
Truy cập trực tuyến: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996790/ https://www.ncbi.nlm.nih.gov/pubmed/34142111 http://dx.doi.org/10.1093/rheumatology/keab460 |